To confirm the metformin-induced downregulation of PCSK9 in olanzapine-associated hepatic steatosis models and explore the specific underlying mechanism for alleviating hepatic lipid accumulation, we determined the mRNA levels of lipid synthesis-related and β-oxidation-related genes in the olanzapine and metformin co-treatment group. This evidence concerns the gene PCSK9 and fatty liver disease.